Akari Therapeutics (AKTX) Stock Price, News & Analysis

+0.01 (+0.85%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
13,919 shs
Average Volume
12,452 shs
Market Capitalization
$9.35 million
P/E Ratio
Dividend Yield
Price Target
AKTX stock logo

About Akari Therapeutics Stock (NASDAQ:AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Stock Price History

AKTX Stock News Headlines

Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Akari Therapeutics PLC (AKTX)
Akari Therapeutics to Present at Biotech Showcase 2024
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($0.03) per share


Free Float
Market Cap
$9.35 million
Not Optionable
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Rachelle Suzanne Jacques (Age 53)
    President, CEO & Director
    Comp: $1.38M
  • Ms. Wendy F. DiCicco CPA (Age 57)
    Interim Chief Financial Officer
  • Ms. Melissa Bradford-Klug (Age 54)
    Chief Operating Officer
  • Dr. Miles Nunn (Age 55)
    Chief Scientific Officer
  • Dr. John F. Neylan III (Age 71)
    M.D., Executive VP & Chief Medical Officer
  • Ms. Beth-Anne Lang
    Senior Vice President of Regulatory Affairs
  • Annie Mack
    Financial Controller

AKTX Stock Analysis - Frequently Asked Questions

How have AKTX shares performed in 2024?

Akari Therapeutics' stock was trading at $3.12 at the beginning of 2024. Since then, AKTX shares have decreased by 62.2% and is now trading at $1.18.
View the best growth stocks for 2024 here

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,500 shares, an increase of 75.0% from the March 15th total of 6,000 shares. Based on an average daily volume of 11,900 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.2% of the shares of the company are sold short.
View Akari Therapeutics' Short Interest

When is Akari Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our AKTX earnings forecast

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) issued its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Shares of Akari Therapeutics reverse split on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akari Therapeutics own?
How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKTX) was last updated on 4/22/2024 by Staff

From Our Partners